Nuclear factor kappaB (NF-kappaB) pathway as a therapeutic target in rheumatoid arthritis.
10.3346/jkms.1999.14.3.231
- Author:
Dae Myung JUE
1
;
Kye Im JEON
;
Jae Yeon JEONG
Author Information
1. Department of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul. dmjue@cmc.cuk.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't ; Review
- Keywords:
Tumor necrosis factor;
NF-kappa B;
Arthritis, rheumatoid;
Interleukin 1;
Monokines;
Anti-inflammatory agents;
Antirheumatic agents
- MeSH:
Animal;
Antirheumatic Agents/therapeutic use*;
Arthritis, Rheumatoid/therapy*;
Arthritis, Rheumatoid/metabolism;
Arthritis, Rheumatoid/immunology;
Cytokines/immunology;
Cytokines/genetics;
Gene Expression Regulation;
Human;
Macrophages/immunology;
NF-kappa B/metabolism*;
NF-kappa B/immunology;
NF-kappa B/biosynthesis;
Tumor Necrosis Factor/genetics
- From:Journal of Korean Medical Science
1999;14(3):231-238
- CountryRepublic of Korea
- Language:English
-
Abstract:
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint swelling and progressive destruction of cartilage and bone. Current RA treatments are largely empirical in origin and their precise mechanism of action is uncertain. Increasing evidence shows that chronic inflammatory diseases such as RA are caused by prolonged production of proinflammatory cytokines including tumor necrosis factor (TNF) and interleukin 1 (IL-1). The nuclear factor kappaB (NF-kappaB) plays an essential role in transcriptional activation of TNF and IL-1. NF-kappaB is induced by many stimuli including TNF and IL-1, forming a positive regulatory cycle that may amplify and maintain RA disease process. NF-kappaB and enzymes involved in its activation can be a target for anti-inflammatory treatment. Aspirin and sodium salicylate inhibit activation of NF-KB by blocking IkappaB kinase, a key enzyme in NF-kappaB activation. Glucocorticoids suppress expression of inflammatory genes by binding glucocorticoid receptor with NF-kappaB, and increasing expression of inhibitory protein of NF-kappaB, IkappaBalpha. Sulfasalazine and gold compounds also inhibit NF-kappaB activation. Continuing advances in our understanding of action mechanism of antirheumatic agents will benefit the future development of RA regimens with greater efficacy and less toxicity.
